{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:11Z","timestamp":1786118771247,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/ppo.0b013e31813fffdd","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T07:03:58Z","timestamp":1209884638000},"page":"226-228","source":"Crossref","is-referenced-by-count":2,"title":["Association of Polymorphisms of FAS-1377, FAS-670, and FASL-844 Genes With Risk Factors for Cutaneous Malignant Melanoma"],"prefix":"10.1097","volume":"13","author":[{"given":"Himabindu","family":"Gaddipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenhard","family":"Herlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/PPO.0b013e318046f214","article-title":"Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis.","volume":"13","author":"Zhang","year":"2007","journal-title":"Cancer J"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2005.05.010","article-title":"Genetic polymorphisms of FAS and FASL (CD95\/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction.","volume":"99","author":"Lai","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jmg.2004.030106","article-title":"Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.","volume":"2","author":"Zhang","year":"2005","journal-title":"J Med Genet"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/carcin\/bgl250","article-title":"Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.","volume":"28","author":"Zhang","year":"2007","journal-title":"Carcinogenesis"},{"key":"R5-2-20210203","first-page":"1030","article-title":"Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst.","volume":"96","author":"Sun","year":"7","journal-title":"2004 Jul"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"11887","DOI":"10.1074\/jbc.M511309200","article-title":"ING3 promotes UV-induced apoptosis via Fas\/caspase-8 pathway in melanoma cells.","volume":"281","author":"Elyassaki","year":"2006","journal-title":"J Biol Chem"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1038\/sj.onc.1203602","article-title":"p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-\u03baB activity and Fas expression.","volume":"19","author":"Ivanov","year":"2000","journal-title":"Oncogene"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000063894","article-title":"Evaluation of soluble Fas ligand as a serological marker for melanoma.","volume":"205","author":"Melzani","year":"2002","journal-title":"Dermatology"},{"key":"R10-2-20210203","first-page":"361","article-title":"Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.","volume":"29","author":"Neuber","year":"2006","journal-title":"Onkologie"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.fpc.0000199501.54466.de","article-title":"Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma.","volume":"16","author":"Li","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.lungcan.2006.09.002","article-title":"Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population.","volume":"54","author":"Park","year":"2006","journal-title":"Lung Cancer"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20050707","article-title":"FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.","volume":"202","author":"Sun","year":"2005","journal-title":"J Exp Med"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00008390-200206000-00010","article-title":"Frequent downregulation of Fas (CD95) expression and function in melanoma: frequent downregulation of Fas (CD95) expression and function in melanoma.","volume":"12","author":"Bullani","year":"2002","journal-title":"Melanoma Res"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1523-1747.2002.01854.x","article-title":"Regulation of Fas-mediated apoptosis by N-ras in melanoma.","volume":"119","author":"Urquhart","year":"2002","journal-title":"J Invest Dermatol"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008390-200510000-00007","article-title":"Experimental therapy using interferon-\u03b3 and anti-Fas antibody against oral malignant melanoma cells.","volume":"15","author":"Kamei","year":"2005","journal-title":"Melanoma Res"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/B:CLIN.0000037727.28386.4e","article-title":"Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.","volume":"21","author":"Hall","year":"2004","journal-title":"Clin Exp Metastasis"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1038\/sj.onc.1207228","article-title":"CD95\/Fas signaling in human melanoma cells: conditional expression of CD95L\/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.","volume":"22","author":"Eberle","year":"2003","journal-title":"Oncogene"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.0022-202X.2004.23572.x","article-title":"Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression.","volume":"124","author":"Fecker","year":"2005","journal-title":"J Invest Dermatol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0b013e31813fffdd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:22Z","timestamp":1786034422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-200707000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31813fffdd","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}